Abstract: Disclosed herein are novel formulations containing relacorilant ((R)-(1-(4-fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo [3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone) that are suitable for administration, including oral administration, to patients suffering from disorders amenable to treatment by glucocorticoid receptor modulators (GRMs). Single unit dosage forms comprise softgel capsules containing these formulations. Such softgel capsules may contain, e.g., relacorilant formulations containing 25 milligrams (mg), 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, or other amounts of relacorilant. These novel formulations and single unit dosage forms may be used to treat diseases and disorders including Cushing's syndrome, Cushing's Disease, and other disorders.

Abstract: Disclosed herein are novel formulations containing relacorilant ((R)-(1-(4-fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone) that are suitable for administration, including oral administration, to patients suffering from disorders amenable to treatment by glucocorticoid receptor modulators (GRMs). Single unit dosage forms comprise softgel capsules containing these formulations. Such softgel capsules may contain, e.g., relacorilant formulations containing 25 milligrams (mg), 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, or other amounts of relacorilant. These novel formulations and single unit dosage forms may be used to treat diseases and disorders including Cushing's syndrome, Cushing's Disease, and other disorders.

Abstract: An apparatus for infusing a liquid that may be espresso, generally provides a body having a gear box at one end portion of the body, a lead screw and a hand crank mechanically communicating with the gearbox, and a valve body and plunger carried at an end portion of the lead screw opposite the gearbox for axial, and non-rotational, movement within a medial chamber defined by an insulated pressure cylinder, the pressure cylinder releasably engaged with a removable a portafilter frame, opposite the gearbox, that carries a removable particulate basket therein, and a carafe releasably engaged with the porta filter frame opposite the pressure cylinder, and a tamper for compressing particulate in the particulate basket.

Abstract: An apparatus for containing, positioning and thermally insulating plural axially aligned beverage containers provides an elongate body, a retention collar that is threadably engaged with the body, a handle carried by the body and a puck that is movable, by a user, between a first position adjacent to an opening of the body and a second position adjacent to an interior bottom surface of the body.

Abstract: The invention relates to methods of synthesizing 2?-deoxy-2?,2?-difluorotetrahydrouridine with increased purity and uniform particle size distribution. In particular, methods of the invention include crystallization and isolation procedures rendering synthetic reaction intermediates. The invention further includes compositions comprising the final compound in highly pure form, including lower number of impurities and lower levels of individual and total impurities.

Abstract: A method of registering frames of a medical video includes, at a computing system, receiving a series of video frames captured by a medical imager imaging a scene of interest of a patient, for a first frame of the series of video frames, determining a plurality of registration estimates for registering the first frame to a second frame of the series of video frames, wherein each registration estimate is determined according to a different one of a plurality of registration methods, determining registration accuracies for the plurality of registration estimates, selecting one of the plurality of registration estimates based on the registration accuracies, and storing in a memory the selected registration estimate as a registration of the first frame to the second frame.

Abstract: The invention relates to methods of synthesizing 2?-deoxy-2?,2?-difluorotetrahydrouridine with increased purity and uniform particle size distribution. In particular, methods of the invention include crystallization and isolation procedures rendering synthetic reaction intermediates. The invention further includes compositions comprising the final compound in highly pure form, including lower number of impurities and lower levels of individual and total impurities.

Abstract: The invention relates to methods of synthesizing 2?-deoxy-2?,2?-difluorotetrahydrouridine with increased purity and uniform particle size distribution. In particular, methods of the invention include crystallization and isolation procedures rendering synthetic reaction intermediates. The invention further includes compositions comprising the final compound in highly pure form, including lower number of impurities and lower levels of individual and total impurities.

Abstract: The present disclosure relates generally to methods for the preparation of Compound (I).

Abstract: Disclosed herein are novel formulations containing relacorilant ((R)-(1-(4-fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone) that are suitable for administration, including oral administration, to patients suffering from disorders amenable to treatment by glucocorticoid receptor modulators (GRMs). Single unit dosage forms comprise softgel capsules containing these formulations. Such softgel capsules may contain, e.g., relacorilant formulations containing 25 milligrams (mg), 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, or other amounts of relacorilant. These novel formulations and single unit dosage forms may be used to treat diseases and disorders including Cushing's syndrome, Cushing's Disease, and other disorders.

Abstract: There is disclosed a pole support for removably supporting a hollow tubular pole, wherein the pole has a latching recess provided along its length. The pole support includes a housing defining a socket that is open at its operative upper end for receiving the pole. A latch is located within the socket and is mounted on a pivot to be pivotally movable between a latched position and an unlatched position. The latch has a latching arm extending on one side of the pivot and a ballast arm extending on an opposed side of the pivot, wherein a centre-of-weight of the latch is located off-centre from the pivot in the ballast arm so that ballast arm normally biases latch under gravity into its latched position.

Abstract: Disclosed herein are novel formulations containing relacorilant ((R)-(1-(4-fluorophenyl)-6-(1-methyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone) that are suitable for administration, including oral administration, to patients suffering from disorders amenable to treatment by glucocorticoid receptor modulators (GRMs). Single unit dosage forms comprise softgel capsules containing these formulations. Such softgel capsules may contain, e.g., relacorilant formulations containing 25 milligrams (mg), 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, or other amounts of relacorilant. These novel formulations and single unit dosage forms may be used to treat diseases and disorders including Cushing's syndrome, Cushing's Disease, and other disorders.

Abstract: An apparatus for infusing a liquid that may be espresso, generally provides a body having a gear box at one end portion of the body, a lead screw and a hand crank mechanically communicating with the gearbox, and a valve body and plunger carried at an end portion of the lead screw opposite the gearbox for axial, and non-rotational, movement within a medial chamber defined by an insulated pressure cylinder, the pressure cylinder releasably engaged with a removable a portafilter frame, opposite the gearbox, that carries a removable particulate basket therein, and a carafe releasably engaged with the porta filter frame opposite the pressure cylinder, and a tamper for compressing particulate in the particulate basket.

Abstract: The invention relates to methods of synthesizing 2?-deoxy-2?,2?-difluorotetrahydrouridine with increased purity and uniform particle size distribution. In particular, methods of the invention include crystallization and isolation procedures rendering synthetic reaction intermediates. The invention further includes compositions comprising the final compound in highly pure form, including lower number of impurities and lower levels of individual and total impurities.

Abstract: Described herein is a method for obtaining a selective estrogen receptor degrader, and compounds used in preparing the selective estrogen receptor degrader.

Abstract: A compound of formula (XXIII) and methods for preparation thereof are provided (XXIII).

Abstract: An apparatus for containing, positioning and thermally insulating plural axially aligned beverage containers provides an elongate body, a retention collar that is threadably engaged with the body, a handle carried by the body and a puck that is movable, by a user, between a first position adjacent to an opening of the body and a second position adjacent to an interior bottom surface of the body.

Abstract: Disclosed herein are novel formulations containing relacorilant ((R)-(1-(4-fluorophenyl)-6-(1-methyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone) that are suitable for administration, including oral administration, to patients suffering from disorders amenable to treatment by glucocorticoid receptor modulators (GRMs). Single unit dosage forms comprise softgel capsules containing these formulations. Such softgel capsules may contain, e.g., relacorilant formulations containing 25 milligrams (mg), 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, or other amounts of relacorilant. These novel formulations and single unit dosage forms may be used to treat diseases and disorders including Cushing's syndrome, Cushing's Disease, and other disorders.

Abstract: The invention relates to methods of synthesizing 2?-deoxy-2?,2?-difluorotetrahydrouridine with increased purity and uniform particle size distribution. In particular, methods of the invention include crystallization and isolation procedures rendering synthetic reaction intermediates. The invention further includes compositions comprising the final compound in highly pure form, including lower number of impurities and lower levels of individual and total impurities.

Abstract: Disclosed herein are novel formulations containing relacorilant ((R)-(1-(4-fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone) that are suitable for administration, including oral administration, to patients suffering from disorders amenable to treatment by glucocorticoid receptor modulators (GRMs). Single unit dosage forms comprise softgel capsules containing these formulations. Such softgel capsules may contain, e.g., relacorilant formulations containing 25 milligrams (mg), 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, or other amounts of relacorilant. These novel formulations and single unit dosage forms may be used to treat diseases and disorders including Cushing's syndrome, Cushing's Disease, and other disorders.